Dr. Nick Holford to Discuss the Use of Modeling in Clinical Pharmacology in Rosa’s World-Wide Webinar Series, “Impact of Modeling & Simulation in Drug Development”

Rosa & Co. LLC today announced that Dr. Nick Holford will present a webinar “Clinical Pharmacology = Disease Progression + Drug Action” on September 19, 2011 at 4:00 pm EDT (GMT -5:00) as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science industries. This series is geared to illustrate the advantages and applicability of M&S in product discovery, development, and marketing programs.

Dr. Holford’s talk, “Clinical Pharmacology = Disease Progression + Drug Action”, will focus on modeling in clinical pharmacology. “Like many disciplines, clinical pharmacology can be viewed from several perspectives. In the context of a clinical trial of a therapeutic agent, clinical pharmacology provides a conceptual framework for relating drug treatment to responses and differentiating possible mechanisms of action. Disease progression refers to the evolution of a disease over time and typically implies worsening of the disease (but also may include spontaneous recovery). Disease progress on the other hand is a description of the disease and its response to treatment. In the context of simulation and modeling, it is useful to think of clinical pharmacology as a model itself, i.e., the combination of disease progression and drug action.”

Register for this free webinar at www.rosaandco.com/webinar. After registering, a confirmation email will be sent with directions for joining the webinar. More information about the webinar series, an archive of past webinars, and a list of future webinar speakers may be found at www.rosaandco.com/webinar.

Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.

751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.